Loading patent…
AssigneePharmaDesign, Inc.
InventorsMasaki Mori, Keizo Sugimachi, Yoichi Tanaka, Kenji Shibuta, Hiroshi Inoue, Ayumi Matsuyama
Estimating the term…
A method of predicting the effectiveness of radiotherapy for cancer patients. A method of predicting the effectiveness of radiotherapy for cancer patients, which includes the steps of: (a) performing a biopsy to collect cancer cells or cancer tissues from a cancer patient, (b) determining the expression level of hepatoma derived growth factor (HDGF) in the cancer cells or cancer tissues obtained in step (a), and (c) on the basis of the results obtained by the determination in step (b), predicting whether or not a significant treatment effect can be obtained when radiotherapy is carried out on the cancer patient.
A method of predicting the effectiveness of radiotherapy for cancer patients, which comprises the steps of:
A reagent used for predicting the effectiveness of radiotherapy for cancer patients, which comprises, as a functional ingredient, polynucleotide, oligonucleotide or a derivative thereof, which hybridizes with the mRNA of hepatoma derived growth factor (HDGF) under stringent conditions.
A reagent used for predicting the effectiveness of radiotherapy for cancer patients, which comprises, as a functional ingredient, an antibody against hepatoma derived growth factor (HDGF).
A DNA chip used for predicting the effectiveness of radiotherapy for cancer patients, which is obtained by immobilizing polynucleotide or oligonucleotide, which hybridizes with the mRNA of hepatoma derived growth factor (HDGF) or a complementary strand thereof under stringent conditions.
A protein chip used for predicting the effectiveness of radiotherapy for cancer patients, which is obtained by immobilizing an antibody against hepatoma derived growth factor (HDGF).
A method of screening a compound enhancing a treatment effect when radiotherapy is carried out on a cancer patient, said screening method comprising a step of evaluating whether or not the expression level of hepatoma derived growth factor (HDGF) in a human cell is increased by addition of a candidate compound, wherein the activity of enhancing said expression level is the index of a candidate compound which can be an enhancer for the effectiveness of radiotherapy.
Dependencies are inferred from the claim text.